United States· US:61874-075_50b9e7bd-c577-4562-9d26-1d8dcb8cf2ef
Viberzi
A eluxadoline product containing eluxadoline, registered in United States by Allergan, Inc.. The same ATC class is registered in 5 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Eluxadoline is registered in 5 of 19 countries.
Countries holding a registration under ATC A07DA06 (eluxadoline), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Eluxadoline · ATC A07DA06
5 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of eluxadoline costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- United States: $65.57 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Eluxadoline · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- US United States$65.57 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ELUXADOLINE
- Manufacturer
- Allergan, Inc.
- Country
- United States (US)
- ATC code
- A07DA06
- ATC class
- Eluxadoline
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1161874-075-16
- ndc1161874-075-60
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
244 interactions on record for eluxadoline.
Graded by severity as the source publishes them — 25 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eluxadoline · interactions on record
244 records
- 25 severe
- 218 moderate
- 1 minor
Most severe, free to view
- EltrombopagB02BX05severe
- EthanolB05XX04severe
- GemfibrozilC10AB04severe
- RifampicinJ04AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Eluxadoline in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a705b22d-b29d-46b7-b13a-7b141d9d0610 GET /v1/drugs/a705b22d-b29d-46b7-b13a-7b141d9d0610?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "75",
"substance": "ELUXADOLINE",
"productndc": "61874-075",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": "CIV",
"strength_unit": "mg/1",
"application_number": "NDA206940",
"marketing_category": "NDA"
}See everything about eluxadoline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.